secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K/A
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001628280-23-008370
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI amends Q4/FY2022 results: net loss up $1.5M due to goodwill tax adjustment
------------------------------------------------------------------------------

- Net loss for Q4 2022 increased by $1.5M; net income for FY2022 decreased by $1.5M due to tax deductible goodwill adjustment.
- Updated Q4 revenue $71M (+36.6% YoY), gross profit $16M (+87.6% YoY), net loss $11.0M.
- FY2022 ended with $132M cash; added 3 gain share contracts; market count increased to 15.
- Management: surpassed top end of revised 2022 guidance for Revenue, Gross Profit, Adjusted EBITDA.
- Remediated two material weaknesses; continues plan for complex accounting transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000162828023008370/0001628280-23-008370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000162828023008370/toi-20230309.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-008370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer